PYXS
Pyxis Oncology, Inc.Healthcare·Biotechnology
$1.80
$114M market cap
Revenue
$11.0M
Free Cash Flow
$-36.4M
Rev Growth
+0.0%
FCF Margin
-330.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's
2-Year Price History
$1.96-48.4%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -23.9 | -24.4 | -23.3 | -26.0 | -26.0 | -0.0 | 42.5 | 18.3 | 63.5 | -533.7% | -- | -- |
| Act | 2025-Q4 | 11.0 | -15.4 | -18.3 | -18.1 | -10.4 | -10.4 | -0.0 | 66.9 | 18.7 | 62.1 | -203.1% | -- | -- |
Valuation & Metrics
Market Stats
Price$1.80
Market Cap$114M
Enterprise Value$90M
P/S Ratio10.3x
P/FCF--
EV/FCF--
FCF Margin (TTM)-330.0%
FCF Yield-31.9%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$11.0M
Net Income$-41.4M
Free Cash Flow$-36.4M
Revenue Growth (YoY)+0.0%
EBITDA Margin-356.0%
Net Margin-374.9%
FCF Margin-330.0%
CapEx % of Revenue0.0%
SBC % of Revenue18.9%
ROIC-368.4%
WC Change % Rev-47.1%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.0M
Days to Cover5.5
Change (vs Prior)-12.5%
Need at least 2 settlement dates for chart
Employees
Headcount44
Revenue / Employee$250,864
Gross Profit / Employee$250,250
Cash Runway
14.0months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
26.1%(+8.7% YoY)
63 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
4.9%(-1.6% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.4%(+0.4% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| PFIZER INC | $9.2M | $1.56 | +$0 | +$0 | +4.5% | $239M |
| Laurion Capital Management LP | $7.3M | $2.30 | +$293K | +$2.0M | +2.9% | $1.01B |
| GordonMD Global Investments LP | $6.0M | $1.15 | +$0 | +$6.0M | +1.5% | $111M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $3.0M | $1.46 | +$3.0M | +$3.0M | — | $4.04T |
| Palo Alto Investors LP | $1.5M | $1.91 | −$39K | −$39K | -3.0% | $586M |
| 683 Capital Management, LLC | $1.3M | $2.26 | +$6K | +$506K | -2.2% | $1.02B |
| RENAISSANCE TECHNOLOGIES LLC | $1.3M | $1.77 | +$234K | +$448K | +1.2% | $63.91B |
| BlackRock, Inc.Passive | $1.2M | $3.36 | +$7K | −$3.6M | -0.2% | $5.69T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $874K | $2.98 | +$31K | −$747K | +2.3% | $1.61T |
| Longaeva Partners L.P. | $735K | $2.22 | +$0 | +$735K | -0.5% | $2.08B |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $673K | $2.33 | +$585K | +$673K | +0.4% | $23.79B |
| MILLENNIUM MANAGEMENT LLC | $581K | $2.45 | −$504K | −$3.0M | -0.5% | $127.40B |
| MARSHALL WACE, LLP | $517K | $2.49 | −$52K | +$517K | +0.6% | $92.71B |
| Decheng Capital LLC | $477K | $1.80 | +$0 | +$0 | -1.4% | $661M |
| JANE STREET GROUP, LLCMM | $445K | $1.88 | −$703K | +$445K | -0.1% | $92.10B |
| VANGUARD FIDUCIARY TRUST COPassive | $439K | $1.46 | +$439K | +$439K | — | $395.83B |
| UBS Group AG | $371K | $1.75 | −$202K | −$208K | -0.3% | $562.11B |
| STATE STREET CORPPassive | $363K | $3.21 | +$11K | −$998K | -0.2% | $2.89T |
| XTX Topco Ltd | $292K | $1.87 | −$130K | +$292K | -1.9% | $5.74B |
| ACADIAN ASSET MANAGEMENT LLC | $209K | $1.46 | +$148K | +$87K | -0.5% | $70.48B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+2.04%
avg per quarter
Holders (ex-self)
+1.90%
excl. this stock
Buyers (this Q)
+1.49%
23 buyers · $0.01B in
Sellers (this Q)
+0.45%
36 sellers · $0.00B out
alpha coverage: 91% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+1.0%
how holders react when this stock falls
On quiet Qs
+41.9%
−10% to +10% baseline
On rallies (+10%+)
-2.7%
how they react when this stock rises
Holders' portfolio flow this Q
-8.3%
outflows — trims may be forced
Sellers' portfolio flow this Q
+6.5%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-15.2%
Holder mid (any stock)
-11.0%
Holder rally (any stock)
-8.2%
Biggest decreases this quarter
HealthInvest Partners ABexited−$710KJANE STREET GROUP, LLC−$703Kα-0.1MILLENNIUM MANAGEMENT LLC−$504Kα-0.5ExodusPoint Capital Management, LPexited−$365KUBS Group AG−$202Kα-0.3XTX Topco Ltd−$130Kα-1.9Quadrature Capital Ltdexited−$116KOMERS ADMINISTRATION Corpexited−$77KMARSHALL WACE, LLP−$52Kα+0.6TWO SIGMA INVESTMENTS, LP−$47Kα-0.9
New buyers this quarter
Top-5 holders · 69.3%
PFIZER INC--
Laurion Capital Management LP--
GordonMD Global Investments LP--
VANGUARD CAPITAL MANAGEMENT LLC--
Palo Alto Investors LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.—RTW INVESTMENTS, LP—PERCEPTIVE ADVISORS LLC—BVF INC/IL—Deep Track Capital, LP—CITADEL ADVISORS LLC61KLaurion Capital Management LP5.0MPFIZER INC7.0MJANUS HENDERSON GROUP PLC—BALYASNY ASSET MANAGEMENT LLC743
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$6.0023330.0%
Last Year (5 analysts)$6.2024440.0%
Current Price$1.80
Analyst Ratings
7
2
Buy: 7Hold: 2Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
40.0%retail-5.3pp
10.6%dark+1.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Pyxis Oncology: Evaporating Liquidity Meets a 35% Dilution Overhang
Overall Risk
8/10
Fraud
2/10
Dilution
9/10
Insolvency
8/10
Earnings Overstated
3/10
Hidden Liabilities
4/10
Legal
2/10
Audit Warnings
5/10
Hidden Upside
2/10
Contextually Acceptable
6/10